Chemomab Therapeutics Ltd. American Depositary Share (CMMB) is a publicly traded Healthcare sector company. As of November 19, 2026, CMMB trades at $1.58 with a market cap of $13.20M and a P/E ratio of 11.56. CMMB moved +2.19% today. Year to date, CMMB is -15.56%; over the trailing twelve months it is -42.16%. Its 52-week range spans $0.92 to $5.88. Rallies surfaces CMMB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Chemomab Therapeutics Q3 2026 net loss triples year over year to $5.1 million: Chemomab Therapeutics reported a third-quarter 2026 net loss of $5.1 million, triple the year-earlier amount, while cash and short-term bank deposits fell 30% from June 30 to $4.7 million. Its proposed merger with Scipher Medicine is expected to close in Q1 2027, subject to shareholder approval and closing conditions.
| Metric | Value |
|---|---|
| Price | $1.58 |
| Market Cap | $13.20M |
| P/E Ratio | 11.56 |
| EPS | $0.12 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.88 |
| 52-Week Low | $0.92 |
| Volume | 37 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-27.65M |
| Gross Margin | 0.00% |
CMMB analyst coverage data. Average price target: $0.00.